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The overarching paradigm for the activation of class III and V receptor tyrosine
kinases (RTKs) prescribes cytokine-mediated dimerization of the receptor
ectodomains and homotypic receptor–receptor interactions. However, structural
studies have shown that the hematopoietic receptor FLT3, a class III RTK, does
not appear to engage in such receptor–receptor contacts, despite its efficient
dimerization by dimeric FLT3 ligand (FL). As part of efforts to better
understand the intricacies of FLT3 activation, we sought to engineer a
monomeric FL. It was found that a Leu27Asp substitution at the dimer
interface of the cytokine led to a stable monomeric cytokine (FLL27D) without
abrogation of receptor binding. The crystal structure of FLL27D at 1.65 Å
resolution revealed that the introduced point mutation led to shielding of the
hydrophobic footprint of the dimerization interface in wild-type FL without
affecting the conformation of the FLT3 binding site. Thus, FLL27D can serve as a
monomeric FL variant to further interrogate the assembly mechanism of
extracellular complexes of FLT3 in physiology and disease.
1. Introduction
Approximately 30% of newly diagnosed patients with acute
myeloid leukemia (AML) harbor mutations in FMS-like
tyrosine kinase receptor 3 (FLT3), which confer a poor disease
prognosis (recently reviewed by Daver et al., 2019). While the
majority of such cases entail FLT3 with internal tandem
duplications (ITDs) in the intracellular juxtamembrane region
of the receptor (Nagel et al., 2017; Tallman et al., 2019; Daver
et al., 2019), somatic mutations in the extracellular and
transmembrane domains of FLT3 have also been identified
and at least one of them has been confirmed to be a driver
mutation (Forbes et al., 2008; Fröhling et al., 2007). FLT3 is a
transmembrane receptor that is expressed on the surface of
early hematopoietic progenitor cells and dendritic cells. The
receptor is a member of the class III tyrosine kinase receptors
(RTK-IIIs), which include CSF-1R, KIT, PDGFR and
PDGFR, which are all characterized by a conserved modular
architecture featuring an extracellular domain (ECD)
comprising five Ig-like domains, a single membrane-spanning
helix (TM) followed by a juxtamembrane (JM) region, and
finally an intracellular tyrosine kinase domain (TKD) (Fig. 1a;
Lemmon & Schlessinger, 2010; Verstraete & Savvides, 2012).
Due to their highly similar build and the dimeric nature of
their cognate cytokine ligands, RTK-IIIs are thought to be
activated by similar mechanisms (Verstraete & Savvides,
2012). The binding of a dimeric cytokine to an RTK-III
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induces receptor dimerization that results in transactivation of
the auto-inhibited tyrosine kinase domains and the activation
of downstream signaling pathways (Fig. 1a). While the intra-
cellular activation mechanism of RTK-III is conserved in all
RTK-IIIs, it has been shown that ligand binding to the
membrane-distal domains takes place by homotypic receptor–
receptor contacts that are mediated by the membrane-
proximal Ig-like domains D4 and/or D5. Although such
ligand-induced extracellular homotypic receptor interactions
have been shown to be present in most RTK-IIIs (Elegheert et
al., 2011; Felix et al., 2013, 2015; Yuzawa et al., 2007; Chen et
al., 2015), they are absent in FLT3, as supported by the ‘open
horseshoe’ structures of its complexes revealed via X-ray
crystallography and negative-stain electron microscopy
(Verstraete, Vandriessche et al., 2011). Furthermore, the
removal of two membrane-proximal domains of FLT3 resulted
in only a moderate change in affinity for the ligand as deter-
mined by isothermal titration calorimetry, suggesting that these
domains do not contribute significantly to the overall affinity
of FLT3 for its cytokine (Verstraete, Vandriessche et al., 2011).
As a consequence of the clear correlation between AML
and mutations in FLT3, therapeutic targeting of FLT3 has
been intensely pursued in industry and academia for over two
decades (Badar et al., 2015; Leick & Levis, 2017). With a few
notable exceptions, most efforts have focused on the devel-
opment of tyrosine kinase inhibitors addressing the intra-
cellular domains of FLT3. With the advent of driver somatic
mutations in the extracellular regions of FLT3, we hypothe-
sized that more in-depth insights into the basic principles
underlying FLT3 receptor activation could possibly reveal
novel approaches to tackle constitutively activated oncogenic
receptor variants. Indeed, despite having crystallographic
models of FL and its complex with the ectodomains of FLT3
(Verstraete, Vandriessche et al., 2011), the absence of struc-
tural insights into the possible inactive conformation of FLT3
and the conformational changes required to transition to an
activated receptor–cytokine complex render our under-
standing of the extracellular complex principles incomplete.
To expand our molecular toolkit towards broadening the
structural and mechanistic insights into FL–FLT3 assembly, we
sought to engineer a monomeric variant of FL. The rationale
behind such an endeavor was manifold. Firstly, a monomeric
variant could be of use for the dissection of cytokine-mediated
activation principles, as has been shown for CSF-1 (Elegheert
et al., 2012). Indeed, it has been suggested that Ig domain 1 of
FLT3 could be involved in an inhibitory cis interaction with
the membrane-proximal domains of the extracellular region
(Verstraete & Savvides, 2012). Secondly, a monomeric ligand
could be a starting point for the further engineering of tools to
dissect receptor-activation principles in cellular assays, as
previously illustrated for stem-cell factor variants (Ho et al.,
2017; Tilayov et al., 2020) or as an in vitro binding probe that
allows the discrimination of properly folded, binding-prone
receptor species. Finally, we hypothesized that a non-
activating, albeit receptor-binding-competent, variant of FL
could lead to the stabilization of mechanistically relevant
conformational states of FLT3.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Production of recombinant FLT3 ligands in Escher-
ichia coli. Recombinant wild-type FL (FLWT) and its
Leu27Asp mutant (FLL27D) were produced according to
previously published methods (Table 1; Verstraete et al., 2009).
Briefly, both proteins were expressed in an E. coli Rosetta-
gami(DE3) bacterial strain (Novagen) as inclusion bodies. The
harvested cell pellets were resuspended in lysis buffer (50 mM
Tris pH 8.0, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA)
and lysed by sonication. Inclusion bodies were isolated,
washed and solubilized in guanidine buffer (6 M guanidinium
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Figure 1
(a) FLT3 belongs to the class III receptor tyrosine kinase family, the members of which are characterized by a conserved modular build and activation
mechanism. For all RTK-IIIs, cytokine ligands simultaneously bind to the membrane-distal domains (yellow; D1, D2 and/or D3) of two cognate
receptors. Although this interaction has been shown to facilitate homotypic interactions between membrane-proximal domains (blue; D4 and/or D5) of
almost all RTK-IIIs, this has not yet been demonstrated for the FL–FLT3 complex. The generation of such a ternary complex, possibly involving
interactions of the transmembrane domains (TM), invokes a transphosphorylation of the inhibitory juxtamembrane (JM) domain, eventually resulting in
fully activated kinase activity. (b) The dimeric interface of FL is centered around Leu27. A cartoon representation of FL (PDB entry 1ete; Savvides et al.,
2000) is shown with the constituting protomers colored green and sand yellow. Coloring according to the Eisenberg hydrophobicity scale (inset, surface
representation; red is more hydrophobic) illustrates how Leu27 from each protomer (blue) is inserted into the hydrophobic interior of the other one.
hydrochloride, 100 mM NaH2PO4, 10 mM Tris, 10 mM
2-mercaptoethanol pH 8.0) by gentle stirring at 40C, followed
by the strict application of previously published protocols
(Verstraete et al., 2009).
2.1.2. Expression of recombinant proteins in mammalian
cells and purification. The cDNA sequence coding for human
FLT3 domains 1–5 (FLT3D1–D5; residues Met1–Asp541) was
obtained from Verstraete et al. (2009) and Verstraete,
Remmerie et al. (2011). Constructs for transient mammalian
expression of secreted proteins carrying a C-terminal
thrombin-cleavable AviTag followed by a hexahistidine
sequence were cloned in the pHLsec vector (Aricescu et al.,
2006). For the generation of stable cell lines, similar constructs
were generated in the pcDNA4/TO vector (Thermo Fisher
Scientific).
A monoclonal stable HEK293S MGAT1/ TR+ cell line
(Reeves et al., 2002) was generated and grown to 90%
confluence in the presence of 50 mg ml1 zeocin (Verstraete,
Remmerie et al., 2011). To induce expression, the growth
medium was replaced by serum-free medium supplemented
with 2 mg ml1 tetracycline and 3.6 mM valproic acid. After
4–5 days of transient or tetracycline-induced expression, the
conditioned medium was harvested, cleared of cellular debris
by centrifugation and filtered through a 22 mm cutoff bottle-
top filter. Recombinant hexahistine-tagged proteins were
captured from the conditioned medium by IMAC purification
using a cOmplete His-tag purification column (Roche). After
elution with 500 mM imidazole, the eluate was concentrated
and further purified by size-exclusion chromatography using
HiLoad 16/60 Superdex 75/200 columns (GE Healthcare) with
HBS buffer (20 mM HEPES pH 7.4, 150 mM NaCl) as the
running buffer. Protein purity was assessed by SDS–PAGE.
2.1.3. Size-exclusion chromatography coupled to multi-
angle laser light scattering (SEC-MALLS). Recombinant
proteins and complexes thereof were concentrated to
1 mg ml1 and injected onto a Superdex 200 Increase column
(GE Healthcare) inline with an ultraviolet detector
(Shimadzu), a multi-angle laser light scattering miniDAWN
TREOS (Wyatt) and an Optilab T-rEX refractometer (Wyatt)
at 25C. HBS was used as the running buffer at a flow of
0.5 ml min1. Data were analyzed using the ASTRA6 software
(Wyatt). For the analysis of glycosylated protein species,
conjugate analysis was performed using theoretical protein
extinction coefficients and a dn/dc value of 0.16 for the glycan
modifier (Bloch et al., 2018).
2.2. Crystallization
Recombinant FLL27D was treated with 1 U mg
1 thrombin
(New England Biolabs) overnight to remove the hexahistidine
purification tag. Subsequently, thrombin and the cleaved
peptide tag were separated from FLL27D by size-exclusion
chromatography. Sitting-drop vapor-diffusion crystallization
trials were set up using a Mosquito crystallization robot (SPT
Labtech) in nanolitre-scale Swissci 96-well triple-drop plates
(Table 2). The protein plates were incubated at 293 K.
Commercially available sitting-drop crystallization screens
from Molecular Dimensions and Hampton Research were
used to screen for conditions allowing crystal nucleation and
growth. Seeding of crystallization conditions was performed
using the Seed Bead Kit (Hampton Research) following the
contemporary protocol.
2.3. Data collection and processing
X-ray diffraction experiments were performed at 100 K on
the PROXIMA-1 beamline at SOLEIL, Gif-sur-Yvette,
France. Two wedges of diffraction data (1–90 and 120–180)
were indexed, integrated and scaled into a single data set using
the XDS suite (Kabsch, 2010).
2.4. Structure solution and refinement
The initial phases were obtained by maximum-likelihood
molecular replacement in Phaser as implemented in the CCP4
package (McCoy et al., 2007; Winn et al., 2011) using a search
model generated from the X-ray structure of FL (PDB entry
1ete; Savvides et al., 2000). Structure building and refinement
were performed iteratively using Coot (Emsley et al., 2010),
Phenix (Liebschner et al., 2019) and BUSTER (Bricogne et al.,
2011). Final refinement was performed using BUSTER 2.10.3.
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Table 2
Crystallization.
Method Microseeding in combination with vapor
diffusion
Plate type Swissci 96-well 3-drop plates
Temperature (K) 293
Protein concentration (mg ml1) 22
Buffer composition of protein
solution
20 mM HEPES, 150 mM NaCl pH 7.4
Composition of reservoir solution 2.0 M ammonium sulfate, 0.1 M HEPES
pH 5.0
Volume and ratio of drop 1:1









Expression host E. coli Rosetta-gami
Complete amino-acid sequence
















3. Results and discussion
3.1. Engineering strategy to monomerize FL
Mature wild-type FL belongs to the structural family of
short-chain four-helical bundle cytokines and consequently
exhibits a noncovalently linked homodimeric structure, in
which the two protomers interact head to head (Savvides et al.,
2000). The availability of several crystallographic models of
FL, both unbound (PDB entry 1ete) and in complex with its
receptor (PDB entries 3qs7 and 3qs9), provided a structural
basis for the development of a strategy to disrupt the dimeric
interface of FL without introducing significant changes in the
receptor-binding epitope (Savvides et al., 2000; Verstraete,
Vandriessche et al., 2011). Following the strategy used to
monomerize CSF-1 (Elegheert et al., 2012), several constructs
were generated with a tandem duplication of the dimer
epitope (residues 18–30), some of which had one or multiple
point mutations at sites playing a key role at the dimeric
interface. However, despite extensive optimization of the
purification protocols, we did not succeed in purifying a
monomeric species that was stable in solution. Therefore, we
resorted to a more targeted approach by introducing a single
point mutation targeting Leu27 at the heart of the dimeric
interface (Fig. 1b). In each protomer, Leu27 is located at the
tip of a loop formed by residues Leu26–Gln29, protruding into
the hydrophobic interior of the four-helical bundle of the
accompanying protomer. By mutating Leu27 to an aspartate,
we hypothesized that the entropic penalty for burying a
charged residue in the hydrophobic interior of the second
protomer would be detrimental for any dimerization event to
occur. Interestingly, previous work by Graddis et al. (1998)
identified a Leu27-to-proline mutation in FL, based on
random mutagenesis, that was deficient in dimerization at low
protein concentrations.
3.2. FLL27D is monomeric and engages in a 1:1 stoichiometric
complex with FLT3
The expression of FLL27D in E. coli followed by in vitro
refolding of FLL27D (Verstraete et al., 2009) led to a stable and
monodisperse protein that eluted in a size-exclusion chroma-
tography (SEC) experiment as a protein with a substantially
reduced hydrodynamic radius (Rhyd) compared with wild-type
FL (FLWT; Fig. 2, green and gray curves). Multi-angle laser
light scattering (SEC-MALLS) analysis of these proteins
during elution from SEC led to molecular-weight determina-
tions of 35 and 17 kDa for FLWT and FLL27D, respectively
(Fig. 2b). Importantly, no concentration-dependent dimeriza-
tion could be detected even at concentrations as high as
95.83 mM (1.7 mg ml1). We concluded that these experi-
mentally determined values are in excellent agreement with
their theoretical molecular weights and confirmed that FLL27D
is indeed a monomeric species in solution.
To assess whether the monomer-inducing point mutation at
position 27 affected the FLT3 binding site, which is localized
close to the N-terminal region of FL (residues 6–13), we
investigated its ability to form a complex with the extracellular
region of recombinant human FLT3 comprising domains 1–5
(FLT3D1–D5; Verstraete, Remmerie et al., 2011). The titration
of a 20% molar excess of FLL27D against FLT3D1–D5 and
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Figure 2
FLL27D is a stable monomer capable of binding only one FLT3 molecule. (a) SEC-MALLS characterization of FLWT, FLL27D and receptor complexes
thereof. Elution profile monitored by the forward and right-angle laser detector (left axis) plotted against the SEC retention volume and overlaid with
the measured molecular weight (right axis). FLWT (green) is able to recruit two FLT3 molecules (yellow) into complex formation (blue), whereas FLL27D
(gray) binds FLT3 in an equimolar fashion (red). (b) Summary of the predicted molecular weights, based on the amino-acid sequence, and the MALLS-
measured molecular weights. Further glycoprotein conjugate analysis of the latter allowed part of the mass to be attributed to the glycan content.
subsequent SEC-MALLS analysis resulted in a predominantly
monodisperse species with an Rhyd exceeding that of both
molecules alone (Fig. 2a, red curve). With only an excess of
FLL27D detected, this shift indicates that despite its monomeric
nature, FLL27D was still able to recruit all available receptor
molecules into complex formation. The molecular species has
a molecular mass of 70 kDa as determined by SEC-MALLS,
which is well below that of an FL-mediated receptor complex
(152 kDa; Fig. 2b) and therefore allowed us to infer that the
apparent FLL27D–FLT3 complex consists of one molecule of
FLL27D and one molecule of FLT3.
3.3. Structural differences between FLL27D and FLWT are
limited to the dimerization-interface region
To further validate that mutation of Leu27 to aspartate does
not compromise the overall fold of the molecule, we pursued
structural characterization of FLL27D by X-ray crystallography.
Initial crystallization trials resulted in the identification of
multiple crystallization conditions across a wide pH range, all
characterized by a high concentration (>1.8 M) of ammonium
sulfate. Subsequent optimization of these initial hits led to
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Table 3
Data collection and processing.
Values in parentheses are for the outer shell.




Crystal-to-detector distance (mm) 321.8
Rotation range per image () 0.1
Total rotation range () 180
Exposure time per image (s) 0.2
Space group P1
a, b, c (Å) 28.30, 43.49, 46.36
, ,  () 82.82, 85.41, 85.10
Mosaicity () 0.105
Resolution range (Å) 18.42–1.65 (1.709–1.650)
Total No. of reflections 70278 (4053)
No. of unique reflections 24967 (1712)
Completeness (%) 94.9 (89.2)
Multiplicity 2.81 (2.37)
hI/(I)i 10.6 (2.33)
Overall B factor from Wilson plot (Å2) 16.95
Rmeas (%) 7.7 (56.7)
CC1/2 (%) 99.6 (72.8)
Table 4
Structure refinement.
Values in parentheses are for the outer shell.
Resolution range (Å) 18.42–1.65 (1.709–1.65)
No. of reflections, working set 24910 (2403)
No. of reflections, test set 1246 (120)
Final Rcryst 0.1643
Final Rfree 0.2026





No. of protein residues 269
R.m.s.d., bond lengths (Å) 0.017
R.m.s.d., angles () 1.49
Ramachandran favored (%) 98.11
Ramachandran allowed (%) 1.89
Ramachandran outliers (%) 0.00
Rotamer outliers (%) 0.00
Clashscore 8.42





No. of TLS groups 1
Figure 3
Representative crystal morphologies and corresponding X-ray diffraction from crystals of FLL27D. (a) Representative image of a crystallization drop
containing crystals of FLL27D displaying macroscopic crystal-growth pathologies. (b) Test X-ray diffraction image from the crystal that resulted in the
data set used for obtaining the structure of the monomeric FLL27D variant reported here. Resolution shells are displayed as circles. A close-up of the
diffraction image (inset) reveals severe diffraction pathologies, including multiple lattices.
crystals that diffracted synchrotron X-rays to high resolution,
although all diffraction patterns showed signs of multiple
crystal lattices (Fig. 3). Nevertheless, we were able to index at
least one crystal into a single crystal lattice in space group P1
and used the obtained data to determine the crystal structure
to 1.65 Å resolution (Tables 3 and 4, Fig. 4).
The obtained crystal structure of FLL27D superimposes very
well with a single protomer of FLWT (Fig. 4a). Indeed, not
taking the B–A loop (residues 25–30) into account, the
average root-mean-square deviation (r.m.s.d.) with FLWT
(PDB entry 1ete; Savvides et al., 2000) is only 0.851 Å, indi-
cating no large structural changes in the overall conformation
of FLL27D. Given the observation that FLL27D still binds FLT3,
it comes as no surprise that the absence of structural deviation
from FLWT remains valid for residues 6–13, which are all key
players in the largest interaction site of the FL–FLT3 epitope
(Verstraete, Vandriessche et al., 2011). Importantly, although
the triclinic unit cell contains two copies of FLL27D (Fig. 4b)
with apparent twofold rotational symmetry, the observed
apparent symmetry axis is dramatically distinct in direction
and context from the twofold-symmetry axis in dimeric FLWT
(Fig. 4a, inset). Likewise, no combination of symmetry rela-
tions can reconstitute the head-to-head dimer resembling
FLWT, despite the fact that the loop containing Asp27 is
located near tightly packed crystal lattice contacts.
Given that the hydrophobic cavity that sheltered Leu27 of
the accompanying FLWT protomer would remain solvent-
exposed after the L27D monomerization event, we wondered
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Figure 4
Structural differences between FLL27D and FLWT are limited to the dimerization-interface region. (a) Superimposition of FLL27D (gray) and FLWT
(green). Crystallographic models of the ligands are shown in cartoon representation with indication of the twofold-symmetry axis (inset) or as ribbon
diagrams (main panel); the side chain of Asp27 in FLL27D is shown as sticks and FLT3 is shown in surface representation. With the exception of the B–
A loop, the main chain of both FLL27D molecules superimposes very well (average C
 r.m.s.d. of 0.85 Å) with the main chain of all four FLWT copies
(PDB entry 1ete). (b) The asymmetric unit of FLL27D crystals features a top-to-top packing of molecules. This topology is distinct from the twofold-
symmetry axis within one FLWT molecule and supports the L27D mutation preventing dimerization even in the context of crystal packing. (c) Detail of
the superimposed B–A loop of FLL27D (gray) and FLWT (green). Loop residues are shown as sticks. Hydrogen bonds are indicated by dashed lines. (d)
Detail of the superimposed B–A loops of FLL27D and FLWT, as viewed from the second FLWT protomer. FLWT is colored according the Eisenberg
hydrophobicity scale (red is more hydrophobic); key residues of FLL27D are shown as sticks. Hydrogen bonds are indicated by dashed lines.
how FLL27D would structurally compensate for this. When
analyzing the conformational changes in the B–A loop
(Fig. 4c), we noticed that Asp27 is able to recruit Tyr30 via an
intramolecular hydrogen bond, thus stabilizing the rotamer
conformation of the latter such that it effectively shields the
hydrophobic cavity that otherwise mediates dimeric FLWT
(Fig. 4d). Thus, we have shown that FL can display structural
plasticity in this region, which may open additional possibi-
lities to engineer this part of FL for structure–function
purposes.
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